Literature DB >> 33486494

Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.

Sabine Kliesch1, Stefanie Schmidt2, Doris Wilborn2, Clemens Aigner3, Walter Albrecht4, Jens Bedke5, Matthias Beintker6, Dirk Beyersdorff7, Carsten Bokemeyer8, Jonas Busch9, Johannes Classen10, Maike de Wit11, Klaus-Peter Dieckmann12, Thorsten Diemer13, Anette Dieing14, Matthias Gockel15, Bernt Göckel-Beining16, Oliver W Hakenberg17, Axel Heidenreich18, Julia Heinzelbecker19, Kathleen Herkommer20, Thomas Hermanns21, Sascha Kaufmann22, Marko Kornmann23, Jörg Kotzerke24, Susanne Krege25, Glen Kristiansen26, Anja Lorch27, Arndt-Christian Müller22, Karin Oechsle8, Timur Ohloff28, Christoph Oing8, Ulrich Otto29, David Pfister18, Renate Pichler30, Heinrich Recken31, Oliver Rick32, Yvonne Rudolph33, Christian Ruf34, Joachim Schirren35, Hans Schmelz36, Heinz Schmidberger37, Mark Schrader38, Stefan Schweyer39, Stefanie Seeling40, Rainer Souchon22, Christian Winter41, Christian Wittekind42, Friedemann Zengerling43, D H Zermann44, Roger Zillmann45, Peter Albers46.   

Abstract

OBJECTIVES: We developed the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up of germ cell tumours (GCT) of the testes in adult patients. We present the guideline content in 2 separate publications. The present second part summarizes therecommendations for the treatment of advanced disease stages and for the management of follow-up and late effects.
MATERIALS AND METHODS: An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search in March 2018), were provided. Thirty-one experts, who were entitled to vote, rated the final clinical recommendations and statements.
RESULTS: Here we present the treatment recommendations separately for patients with metastatic seminoma and non-seminomatous GCT (stages IIA/B and IIC/III), for restaging and treatment of residual masses, and for relapsed and refractory disease stages. The recommendations also cover extragonadal and sex cord/stromal tumours, the management of follow-up and toxicity, quality-of-life aspects, palliative care, and supportive therapy.
CONCLUSION: Physicians and other medical service providers who are involved in the diagnostics, treatment, and follow-up of GCT (all stages, outpatient and inpatient care as well as rehabilitation) are the users of the present guideline. The guideline also comprises quality indicators for measuring the implementation of the guideline recommendations in routine clinical care; these data will be presented in a future publication.
© 2021 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Extragonadal tumours; Follow-up; Germ cell tumour of the testes; Guideline; Metastasis; Non-seminoma; Palliative care; Quality of life; Seminoma; Stromal tumours; Supportive therapy; Systematic review; Therapy; Toxicity

Mesh:

Year:  2021        PMID: 33486494      PMCID: PMC8006578          DOI: 10.1159/000511245

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  1 in total

Review 1.  Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.

Authors:  Sabine Kliesch; Stefanie Schmidt; Doris Wilborn; Clemens Aigner; Walter Albrecht; Jens Bedke; Matthias Beintker; Dirk Beyersdorff; Carsten Bokemeyer; Jonas Busch; Johannes Classen; Maike de Wit; Klaus-Peter Dieckmann; Thorsten Diemer; Anette Dieing; Matthias Gockel; Bernt Göckel-Beining; Oliver W Hakenberg; Axel Heidenreich; Julia Heinzelbecker; Kathleen Herkommer; Thomas Hermanns; Sascha Kaufmann; Marko Kornmann; Jörg Kotzerke; Susanne Krege; Glen Kristiansen; Anja Lorch; Arndt-Christian Müller; Karin Oechsle; Timur Ohloff; Christoph Oing; Ulrich Otto; David Pfister; Renate Pichler; Heinrich Recken; Oliver Rick; Yvonne Rudolph; Christian Ruf; Joachim Schirren; Hans Schmelz; Heinz Schmidberger; Mark Schrader; Stefan Schweyer; Stefanie Seeling; Rainer Souchon; Christian Winter; Christian Wittekind; Friedemann Zengerling; Dirk-Henrik Zermann; Roger Zillmann; Peter Albers
Journal:  Urol Int       Date:  2021-01-07       Impact factor: 2.089

  1 in total
  10 in total

1.  How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.

Authors:  Stefanie Schmidt; Carsten Bokemeyer; Christian Winter; Friedemann Zengerling; Jonas Busch; Julia Heinzelbecker; David Pfister; Christian Ruf; Julia Lackner; Peter Albers; Sabine Kliesch
Journal:  World J Urol       Date:  2022-05-12       Impact factor: 4.226

2.  Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review.

Authors:  Jonas Busch; Stefanie Schmidt; Peter Albers; Julia Heinzelbecker; Sabine Kliesch; Julia Lackner; David Pfister; Christian Ruf; Christian Winter; Friedemann Zengerling; Dirk Beyersdorff
Journal:  World J Urol       Date:  2022-01-17       Impact factor: 4.226

3.  First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.

Authors:  David Pfister; Karin Oechsle; Stefanie Schmidt; Jonas Busch; Carsten Bokemeyer; Axel Heidenreich; Julia Heinzelbecker; Christian Ruf; Christian Winter; Friedemann Zengerling; Sabine Kliesch; Peter Albers; Christoph Oing
Journal:  World J Urol       Date:  2022-02-28       Impact factor: 4.226

Review 4.  [Follow-up of testicular germ cell tumors-historical aspects and current recommendations].

Authors:  Klaus-Peter Dieckmann; Christian Guido Ruf; Raphael Gübitz; Christian Wülfing; Friedemann Zengerling
Journal:  Urologe A       Date:  2022-04-06       Impact factor: 0.639

5.  Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review.

Authors:  Friedemann Zengerling; Dirk Beyersdorff; Jonas Busch; Julia Heinzelbecker; David Pfister; Christian Ruf; Christian Winter; Peter Albers; Sabine Kliesch; Stefanie Schmidt
Journal:  World J Urol       Date:  2022-07-29       Impact factor: 3.661

6.  Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma.

Authors:  Klaus-Peter Dieckmann; Markus Klemke; Francesca Grobelny; Arlo Radtke; Inken Dralle-Filiz; Christian Wülfing; Gazanfer Belge
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

7.  Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours.

Authors:  Carsten-Henning Ohlmann; Matthias Saar; Laura-Christin Pierchalla; Miran Zangana; Alena Bonaventura; Michael Stöckle; Stefan Siemer; Julia Heinzelbecker
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

Review 8.  Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging.

Authors:  Gamal Anton Wakileh; Christian Ruf; Axel Heidenreich; Klaus-Peter Dieckmann; Catharina Lisson; Vikas Prasad; Christian Bolenz; Friedemann Zengerling
Journal:  World J Urol       Date:  2021-11-15       Impact factor: 4.226

9.  Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients.

Authors:  Ramin Madanchi; Nils W Engel; Winfried Alsdorf; Christoph Oing; Christian Frenzel; Finn-Ole Paulsen; Carsten Bokemeyer; Christoph Seidel
Journal:  Bone Marrow Transplant       Date:  2022-02-21       Impact factor: 5.174

Review 10.  [Diagnosis and treatment of Leydig cell tumors].

Authors:  Sabine Kliesch
Journal:  Urologe A       Date:  2021-07-05       Impact factor: 0.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.